23价肺炎球菌多糖疫苗降低死亡率:一项系统回顾和荟萃分析

IF 8.5 Q1 RESPIRATORY SYSTEM
Muhammed Shabil, Shilpa Gaidhane, Suhas Ballal, Sanjay Kumar, Mahakshit Bhat, Shilpa Sharma, M Ravi Kumar, Sarvesh Rustagi, Mahalaqua Nazli Khatib, Nishant Rai, Sanjit Sah, Edward Mawejje, Ganesh Bushi, Kiran Bhopte, Rachna Kathuria, Ambanna Yappalparvi
{"title":"23价肺炎球菌多糖疫苗降低死亡率:一项系统回顾和荟萃分析","authors":"Muhammed Shabil, Shilpa Gaidhane, Suhas Ballal, Sanjay Kumar, Mahakshit Bhat, Shilpa Sharma, M Ravi Kumar, Sarvesh Rustagi, Mahalaqua Nazli Khatib, Nishant Rai, Sanjit Sah, Edward Mawejje, Ganesh Bushi, Kiran Bhopte, Rachna Kathuria, Ambanna Yappalparvi","doi":"10.1186/s41479-024-00149-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality. This systematic review and meta-analysis aimed to evaluate the efficacy of PPV23 in reducing all-cause and pneumonia-related mortality among adults.</p><p><strong>Methods: </strong>A systematic search was conducted across PubMed, Embase, and Web of Science, focusing on studies that evaluated the mortality outcomes of adults vaccinated with PPV23 compared to non-vaccinated adults. Both randomized controlled trials (RCTs) and observational studies were included, while case reports, case series, and non-human studies were excluded. Data extraction and quality assessment were facilitated by Nested Knowledge software, using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs.</p><p><strong>Results: </strong>The search yielded 826 records, with 19 studies meeting the inclusion criteria. The pooled analysis of four RCTs showed no significant reduction in all-cause mortality (RR = 1.030; 95% CI: 0.945, 1.122). However, analysis of pneumonia-related mortality across various studies indicated a significant reduction (HR = 0.504; 95% CI: 0.316, 0.693). Moderate to high heterogeneity was noted in mortality studies, and a potential publication bias was identified.</p><p><strong>Conclusion: </strong>The findings suggest that while PPV23 may not significantly reduce all-cause mortality, it is effective in reducing pneumonia-related mortality among adults, particularly in those at higher risk. These results support the continued use of PPV23 in targeted adult populations, emphasizing the need for more primary studies to explore its effectiveness across diverse groups.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":"16 1","pages":"30"},"PeriodicalIF":8.5000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669219/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis.\",\"authors\":\"Muhammed Shabil, Shilpa Gaidhane, Suhas Ballal, Sanjay Kumar, Mahakshit Bhat, Shilpa Sharma, M Ravi Kumar, Sarvesh Rustagi, Mahalaqua Nazli Khatib, Nishant Rai, Sanjit Sah, Edward Mawejje, Ganesh Bushi, Kiran Bhopte, Rachna Kathuria, Ambanna Yappalparvi\",\"doi\":\"10.1186/s41479-024-00149-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality. This systematic review and meta-analysis aimed to evaluate the efficacy of PPV23 in reducing all-cause and pneumonia-related mortality among adults.</p><p><strong>Methods: </strong>A systematic search was conducted across PubMed, Embase, and Web of Science, focusing on studies that evaluated the mortality outcomes of adults vaccinated with PPV23 compared to non-vaccinated adults. Both randomized controlled trials (RCTs) and observational studies were included, while case reports, case series, and non-human studies were excluded. Data extraction and quality assessment were facilitated by Nested Knowledge software, using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs.</p><p><strong>Results: </strong>The search yielded 826 records, with 19 studies meeting the inclusion criteria. The pooled analysis of four RCTs showed no significant reduction in all-cause mortality (RR = 1.030; 95% CI: 0.945, 1.122). However, analysis of pneumonia-related mortality across various studies indicated a significant reduction (HR = 0.504; 95% CI: 0.316, 0.693). Moderate to high heterogeneity was noted in mortality studies, and a potential publication bias was identified.</p><p><strong>Conclusion: </strong>The findings suggest that while PPV23 may not significantly reduce all-cause mortality, it is effective in reducing pneumonia-related mortality among adults, particularly in those at higher risk. These results support the continued use of PPV23 in targeted adult populations, emphasizing the need for more primary studies to explore its effectiveness across diverse groups.</p>\",\"PeriodicalId\":45120,\"journal\":{\"name\":\"Pneumonia\",\"volume\":\"16 1\",\"pages\":\"30\"},\"PeriodicalIF\":8.5000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669219/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pneumonia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41479-024-00149-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumonia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41479-024-00149-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

背景:由肺炎链球菌引起的肺炎球菌疾病对全球健康造成重大负担,尤其影响老年人和免疫功能低下者等弱势群体。23价肺炎球菌多糖疫苗(PPV23)设计用于预防23种血清型肺炎链球菌。然而,关于其在降低全因死亡率方面的有效性仍存在争议。本系统综述和荟萃分析旨在评估PPV23在降低成人全因死亡率和肺炎相关死亡率方面的疗效。方法:通过PubMed、Embase和Web of Science进行系统搜索,重点研究接种PPV23的成年人与未接种PPV23的成年人的死亡率结果。随机对照试验(rct)和观察性研究均被纳入,而病例报告、病例系列和非人类研究被排除。使用Nested Knowledge软件进行数据提取和质量评估,观察性研究使用纽卡斯尔-渥太华量表,随机对照试验使用Cochrane偏倚风险工具。结果:检索到826条记录,其中19项研究符合纳入标准。4项随机对照试验的合并分析显示,全因死亡率无显著降低(RR = 1.030;95% ci: 0.945, 1.122)。然而,对各种研究中肺炎相关死亡率的分析表明,有显著降低(HR = 0.504;95% ci: 0.316, 0.693)。在死亡率研究中注意到中度至高度的异质性,并确定了潜在的发表偏倚。结论:研究结果表明,虽然PPV23可能不会显著降低全因死亡率,但它可以有效降低成人,特别是高风险人群的肺炎相关死亡率。这些结果支持在目标成人人群中继续使用PPV23,强调需要更多的初步研究来探索其在不同人群中的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis.

Background: Pneumococcal disease, caused by Streptococcus pneumoniae, imposes a significant global health burden, particularly affecting vulnerable groups such as the elderly and immunocompromised. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is designed to protect against 23 serotypes of Streptococcus pneumoniae. However, there is ongoing debate about its effectiveness in reducing all-cause mortality. This systematic review and meta-analysis aimed to evaluate the efficacy of PPV23 in reducing all-cause and pneumonia-related mortality among adults.

Methods: A systematic search was conducted across PubMed, Embase, and Web of Science, focusing on studies that evaluated the mortality outcomes of adults vaccinated with PPV23 compared to non-vaccinated adults. Both randomized controlled trials (RCTs) and observational studies were included, while case reports, case series, and non-human studies were excluded. Data extraction and quality assessment were facilitated by Nested Knowledge software, using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for RCTs.

Results: The search yielded 826 records, with 19 studies meeting the inclusion criteria. The pooled analysis of four RCTs showed no significant reduction in all-cause mortality (RR = 1.030; 95% CI: 0.945, 1.122). However, analysis of pneumonia-related mortality across various studies indicated a significant reduction (HR = 0.504; 95% CI: 0.316, 0.693). Moderate to high heterogeneity was noted in mortality studies, and a potential publication bias was identified.

Conclusion: The findings suggest that while PPV23 may not significantly reduce all-cause mortality, it is effective in reducing pneumonia-related mortality among adults, particularly in those at higher risk. These results support the continued use of PPV23 in targeted adult populations, emphasizing the need for more primary studies to explore its effectiveness across diverse groups.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pneumonia
Pneumonia RESPIRATORY SYSTEM-
自引率
1.50%
发文量
7
审稿时长
11 weeks
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信